Prerpints.org logo
Preprint
Hypothesis

Encapsulated Bacteria with a Light-Repressed Deadman Switch for Liver Gene Delivery

Altmetrics

Downloads

243

Views

119

Comments

0

This version is not peer-reviewed

Submitted:

24 April 2024

Posted:

25 April 2024

Read the latest preprint version here

Alerts
Abstract
Adeno-associated viruses (AAVs) have been used for liver gene therapy. Hemgenix and Roctavian are AAV-based treatments for hemophilia B and A, respectively. They cost $3 million and $2.8 million per dose, respectively. While AAV vectors may eventually be cheaper to mass produce, a bacteria-based DNA delivery system might be much cheaper for patients. Also, “bactofection” would allow for the delivery of much larger DNA packages. Such a bacterial system may now be possible, and a prototype for the liver could possibly be developed immediately.
Keywords: 
Subject: Biology and Life Sciences  -   Biology and Biotechnology

1. Introduction

Adeno-associated viruses (AAVs) can only encode ~5 kb of DNA maximum, which is not sufficient to cure certain individuals with genetic disorders wherein long stretches of nucleotides are affected, e.g., at least some cases of Duchenne muscular dystrophy [1,2,3,4,5,6].
Apparently, “…in principle prime editing can correct up to ~89% of the 75,122 pathogenic human genetic variants in ClinVar…” [7]. New prime editing-based techniques can almost surely cover even more variants [8]. However, multiple proteins/RNAs/DNA molecules (or at least a single, large DNA molecule) may be required in certain cases when more complex molecular machinery must be employed - e.g., if heterochromatin is an issue.
Also, the cost of producing sufficiently high titers of AAV vectors and other viral vectors for therapeutic purposes is very steep [9,10,11].
Intravenously injected lipid nanoparticle (LNP)-encapsulated CRISPR ribonucleoproteins (RNPs) have been successfully utilized in the liver and somewhat in the lungs [12,13]. However, current LNP formulations at least cannot effectively reach or target cells in the CNS, heart, or kidneys after intravenous injection [13,14]. Also, the larger the LNP - the less effective it is at extravasation. Thus, it cannot encapsulate large cargos unless targeted to the liver or spleen. Also, LNP production costs are still substantial - and scaling up the production of new ionizable lipids is not that facile [15,16,17,18].
Intrathecal and intracerebroventricular administration of RNPs, as well as direct intraparenchymal injection of RNPs into the striatum, does not result in widespread CNS editing [19].
A synthetic bacterial vector with low immunogenicity that only delivers to particular organs or organ systems would be of use for multiple reasons.
  • It would be cheap.
  • It could deliver large DNA constructs to use as homologous repair templates or large serine recombinase/CRISPR transposase cargo for individuals with genetic disorders wherein long stretches of nucleotides are affected.
  • May be able to extravasate at least moderately efficiently in most anatomical locales - and then specifically proliferate in the target organ or organ system [20,21]. (Worst case scenario - intraparenchymal injections could be employed.)
  • Flagellar motility of the vector allows for autonomous, widespread delivery throughout the organ or organ system [22].

2. Prototype for the Liver

The Escherichia Coli Nissle 1917 or Salmonella Typhimurium vector could be encapsulated [23] to prevent cytotoxic protein secretion from affecting the tissue environment and substantially attenuate the immune response. It can also be myristoylation negative [24]. One could employ an anti-sepsis small molecule - at least in a mouse model [25]. Dexamethasone would be used to further suppress the immune response and induce the expression of CY3PA in the liver. One would then administer a caged luciferin molecule that is uncaged by CY3PA [26].
The bacteria would express firefly luciferase [27,28] and have a Deadman switch that is sensitive to (blue-shifted) light [29,30,31]. Bacteria that stray outside of the liver - where the luciferin is uncaged - will quickly (stop replicating and) lyse.
When the bacteria in the liver reach a high enough population level (either visualized with an MRI-based reporter gene [32] or just after an experimentally-determined period of time), they can be induced via small molecule to produce a large quantity of CRISPR RNPs [19,33] and lyse.
Theoretically, E. coli Nissle 1917 is endotoxin-free. However, to prevent possible issues from mass lysis, perhaps the small molecule should stop motility immediately - while the gene circuit for lysis can be noisy [34].
Another option would be to use a second Deadman switch; a molecule that the bacteria are exposed to in solution prior to intravenous injection would be gone after injection, and eventually they will just (stop replicating and) lyse naturally.
To deliver DNA and RNA, the bacteria could instead produce large quantities of an engineered T4 bacteriophage [35]. However, this phage is not very efficient at entering eukaryotic cells - or at least escaping the endosome.
Thus, instead of just lysing - after small molecule administration or the second Deadman switch time period ending - it could lose the capsule, enter hepatocytes [36], escape the endosome if necessary [37], overproduce an engineered T4 phage, and lyse [37].

3. Other Organs and Organ Systems

We could identify other enzymes specific to an organ or organ system and develop caged luciferins for those as well. This system does not have to be caged luciferin/luciferin, though, of course. It could be an organ/organ system-specific extracellular protease, for example. This protease could activate regulated intramembrane proteolysis [38] or cleave a pro-peptide that activates a two-component regulatory system [39]. The benefit of such an approach would be that the bacteria themselves would secrete the molecule required for their continued survival - which would be locally activated in the organ or organ system of choice. This might not produce a sufficiently intense signal, though.
Bacteria can also cross the blood-brain barrier after intravenous injection [21,40].
There is a caged luciferin that can be uncaged in the brain - but it also is uncaged in the kidneys [41]. A better strategy - for now at least - would just be to administer a small molecule that is blood-brain barrier-impermeable and that kills any of the synthetic bacteria in the periphery.
In a paper by Dr. Antas et al., it was said that “Although nonviral NPs may tackle the main limitations of their viral counterparts, they have thus far failed to compete with the transduction efficiency achieved by viral vectors in the retina” [42].
Bactofection could be better than AAVs for retinal conditions. A Deadman switch could be used to only allow (limited) bacterial replication in the eye via a small molecule present in an eye-drop solution.
Identifying tissue-specific enzymes should not be very difficult nowadays [43].

References

  1. Spinner NB, Loomes KM, Krantz ID, Gilbert MA. Alagille Syndrome. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, et al., editors. GeneReviews®, Seattle (WA): University of Washington, Seattle; 1993.
  2. Stoller JK, Hupertz V, Aboussouan LS. Alpha-1 Antitrypsin Deficiency. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, et al., editors. GeneReviews®, Seattle (WA): University of Washington, Seattle; 1993.
  3. Myerowitz, R. Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene. Hum Mutat 1997, 9, 195–208. [Google Scholar] [CrossRef]
  4. Butchbach MER. Genomic Variability in the Survival Motor Neuron Genes (SMN1 and SMN2): Implications for Spinal Muscular Atrophy Phenotype and Therapeutics Development. International Journal of Molecular Sciences 2021, 22, 7896. [CrossRef] [PubMed]
  5. Daiger S, Sullivan L, Bowne S. Genes and mutations causing retinitis pigmentosa. Clin Genet 2013, 84, 12203. [CrossRef] [PubMed]
  6. Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers 2021, 7, 1–19. [CrossRef]
  7. Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 2019, 576, 149–57. [CrossRef] [PubMed]
  8. Zheng C, Liu B, Dong X, Gaston N, Sontheimer EJ, Xue W. Template-jumping prime editing enables large insertion and exon rewriting in vivo. Nat Commun 2023, 14, 3369. [CrossRef] [PubMed]
  9. Collins LT, Ponnazhagan S, Curiel DT. Synthetic Biology Design as a Paradigm Shift toward Manufacturing Affordable Adeno-Associated Virus Gene Therapies. ACS Synth Biol 2023, 12, 17–26. [CrossRef] [PubMed]
  10. Becker, Z. Sporting a $3.5M price tag, CSL and uniQure’s hemophilia B gene therapy crosses FDA finish line. Fierce Pharma 2022. https://www.fiercepharma.com/pharma/csl-and-uniqures-hemophilia-b-gene-therapy-scores-approval-35-million-price-tag (accessed December 9, 2023).
  11. Bluebird Bio Secures Deal with Large Commercial Payer for Lyfgenia Amid Price Concerns. BioSpace n.d. https://www.biospace.com/article/bluebird-bio-secures-deal-with-large-commercial-payer-for-lyfgenia-amid-price-concerns/ (accessed January 4, 2024).
  12. Wei T, Sun Y, Cheng Q, Chatterjee S, Traylor Z, Johnson LT, et al. Lung SORT LNPs enable precise homology-directed repair mediated CRISPR/Cas genome correction in cystic fibrosis models. Nat Commun 2023, 14, 7322. [CrossRef] [PubMed]
  13. Chen K, Han H, Zhao S, Xu B, Yin B, Trinidad M, et al. Lung and liver editing by lipid nanoparticle delivery of a stable CRISPR-Cas9 RNP 2023. [CrossRef]
  14. Behr M, Zhou J, Xu B, Zhang H. In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges. Acta Pharmaceutica Sinica B 2021, 11, 2150–71. [CrossRef]
  15. Wang X, Liu S, Sun Y, Yu X, Lee SM, Cheng Q, et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc 2023, 18, 265–91. [CrossRef]
  16. Verma M, Ozer I, Xie W, Gallagher R, Teixeira A, Choy M. The landscape for lipid-nanoparticle-based genomic medicines. Nat Rev Drug Discov 2023, 22, 349–50. [CrossRef] [PubMed]
  17. Shepherd SJ, Han X, Mukalel AJ, El-Mayta R, Thatte AS, Wu J, et al. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines. Proc Natl Acad Sci U S A n.d.;120:e2303567120. [CrossRef]
  18. Mehta M, Bui TA, Yang X, Aksoy Y, Goldys EM, Deng W. Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development. ACS Mater Au 2023, 3, 600–19. [CrossRef] [PubMed]
  19. Stahl EC, Sabo JK, Kang MH, Allen R, Applegate E, Kim SE, et al. Genome editing in the mouse brain with minimally immunogenic Cas9 RNPs. Molecular Therapy 2023, 31, 2422–38. [CrossRef] [PubMed]
  20. Tan X, Petri B, DeVinney R, Jenne CN, Chaconas G. The Lyme disease spirochete can hijack the host immune system for extravasation from the microvasculature. Mol Microbiol 2021, 116, 498–515. [CrossRef] [PubMed]
  21. Sun R, Liu M, Lu J, Chu B, Yang Y, Song B, et al. Bacteria loaded with glucose polymer and photosensitive ICG silicon-nanoparticles for glioblastoma photothermal immunotherapy. Nat Commun 2022, 13, 5127. [CrossRef] [PubMed]
  22. Toley BJ, Forbes NS. Motility is Critical for Effective Distribution and Accumulation of Bacteria in Tumor Tissue. Integr Biol (Camb) 2012, 4, 165–76. [CrossRef] [PubMed]
  23. Harimoto T, Hahn J, Chen Y-Y, Im J, Zhang J, Hou N, et al. A programmable encapsulation system improves delivery of therapeutic bacteria in mice. Nat Biotechnol 2022, 40, 1259–69 . [CrossRef] [PubMed]
  24. Stritzker J, Hill PJ, Gentschev I, Szalay AA. Myristoylation negative msbB-mutants of probiotic E. coli Nissle 1917 retain tumor specific colonization properties but show less side effects in immunocompetent mice. Bioeng Bugs 2010, 1, 139–45 . [CrossRef]
  25. Gawish R, Maier B, Obermayer G, Watzenboeck ML, Gorki A-D, Quattrone F, et al. A neutrophil–B-cell axis impacts tissue damage control in a mouse model of intraabdominal bacterial infection via Cxcr4. eLife n.d.;11:e78291. [CrossRef]
  26. Yevtodiyenko A, Bazhin A, Khodakivskyi P, Godinat A, Budin G, Maric T, et al. Portable bioluminescent platform for in vivo monitoring of biological processes in non-transgenic animals. Nat Commun 2021, 12, 2680 . [CrossRef]
  27. Cronin M, Akin AR, Collins SA, et al. High Resolution In Vivo Bioluminescent Imaging for the Study of Bacterial Tumour Targeting. PLoS One 2012, 7, e30940. [CrossRef]
  28. Dash R, Holsinger KA, Chordia MD, et al. Bioluminescence-Based Determination of Cytosolic Accumulation of Antibiotics in Escherichia coli. 2024. [CrossRef]
  29. Chan CTY, Lee JW, Cameron DE, Bashor CJ, Collins JJ. “Deadman” and “Passcode” microbial kill switches for bacterial containment. Nat Chem Biol 2016, 12, 82–6 . [CrossRef] [PubMed]
  30. Branchini BR, Ablamsky DM, Rosenman JM, Uzasci L, Southworth TL, Zimmer M. Synergistic Mutations Produce Blue-Shifted Bioluminescence in Firefly Luciferase. Biochemistry 2007, 46, 13847–55 . [CrossRef] [PubMed]
  31. Nash AI, McNulty R, Shillito ME, Swartz TE, Bogomolni RA, Luecke H, et al. Structural basis of photosensitivity in a bacterial light-oxygen-voltage/helix-turn-helix (LOV-HTH) DNA-binding protein. Proc Natl Acad Sci U S A 2011, 108, 9449–54 . [CrossRef]
  32. Allouche-Arnon H, Khersonsky O, Tirukoti ND, Peleg Y, Dym O, Albeck S, et al. Computationally designed dual-color MRI reporters for noninvasive imaging of transgene expression. Nat Biotechnol 2022, 40, 1143–9 . [CrossRef] [PubMed]
  33. Yu S, Yang H, Li T, Pan H, Ren S, Luo G, et al. Efficient intracellular delivery of proteins by a multifunctional chimaeric peptide in vitro and in vivo. Nat Commun 2021, 12, 5131 . [CrossRef]
  34. Kannoly S, Gao T, Dey S, Wang I-N, Singh A, Dennehy JJ. Optimum Threshold Minimizes Noise in Timing of Intracellular Events. iScience 2020, 23, 101186 . [CrossRef]
  35. Zhu J, Batra H, Ananthaswamy N, Mahalingam M, Tao P, Wu X, et al. Design of bacteriophage T4-based artificial viral vectors for human genome remodeling. Nat Commun 2023, 14, 2928 . [CrossRef]
  36. Raman V, Van Dessel N, Hall CL, Wetherby VE, Whitney SA, Kolewe EL, et al. Intracellular delivery of protein drugs with an autonomously lysing bacterial system reduces tumor growth and metastases. Nat Commun 2021, 12, 6116 . [CrossRef]
  37. Brumell JH, Tang P, Zaharik ML, Finlay BB. Disruption of the Salmonella-Containing Vacuole Leads to Increased Replication of Salmonella enterica Serovar Typhimurium in the Cytosol of Epithelial Cells. Infect Immun 2002, 70, 3264–70 . [CrossRef]
  38. Heinrich J, Wiegert T. Regulated intramembrane proteolysis in the control of extracytoplasmic function sigma factors. Research in Microbiology 2009, 160, 696–703 . [CrossRef]
  39. Brink KR, Hunt MG, Mu AM, et al. An E. coli display method for characterization of peptide-sensor kinase interactions. Nat Chem Biol 2023, 19, 451–459; [CrossRef] [PubMed]
  40. Arbab M, Matuszek Z, Kray KM, Du A, Newby GA, Blatnik AJ, et al. Base editing rescue of spinal muscular atrophy in cells and in mice. Science 2023, 380, eadg6518. [CrossRef] [PubMed]
  41. Mofford DM, Adams STJr, Reddy GSKK, Reddy GR, Miller SC. Luciferin Amides Enable in Vivo Bioluminescence Detection of Endogenous Fatty Acid Amide Hydrolase Activity. J Am Chem Soc 2015, 137, 8684–7. [CrossRef] [PubMed]
  42. Antas P, Carvalho C, Cabral-Teixeira J, Lemos L de, Seabra MC. Toward low-cost gene therapy: mRNA-based therapeutics for treatment of inherited retinal diseases. Trends in Molecular Medicine 2023, 0. [CrossRef]
  43. Yang RY, Quan J, Sodaei R, Aguet F, Segrè AV, Allen JA, et al. A systematic survey of human tissue-specific gene expression and splicing reveals new opportunities for therapeutic target identification and evaluation 2018, 311563. [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
A Novel Piggyback Strategy for mRNA Delivery Exploiting Adenovirus Entry Biology

Myungeun Lee

et al.

,

2022

Sea Bass Immunization to Downsized Betanodavirus Protein Displayed in The Surface of Dna-Damaged Repair-Less Bacteria

Raquel Lama

et al.

,

2019

In Vitro and In Vivo Evaluation of Human Adenovirus Type 49 as a Vector for Therapeutic Applications

Emily A. Bates

et al.

,

2021

Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated